202 related articles for article (PubMed ID: 22444689)
1. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
2. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.
Burger JA; Schmitt-Gräff A; Bürkle A; Seiler L; Finke J
Leuk Lymphoma; 2006 Nov; 47(11):2427-30. PubMed ID: 17107924
[No Abstract] [Full Text] [Related]
5. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
[TBL] [Abstract][Full Text] [Related]
7. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
8. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
Preisinger C; Schwarz JP; Bleijerveld OB; Corradini E; Müller PJ; Anderson KI; Kolch W; Scholten A; Heck AJ
Leukemia; 2013 Mar; 27(3):743-6. PubMed ID: 22976128
[No Abstract] [Full Text] [Related]
9. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Silver RT; Cortes J; Waltzman R; Mone M; Kantarjian H
Haematologica; 2009 May; 94(5):743-4. PubMed ID: 19407320
[No Abstract] [Full Text] [Related]
10. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
11. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
12. Unusual extramedullary relapse of CML.
Smaradottir A; Kapur D; Bilgrami S
Ann Oncol; 2004 Aug; 15(8):1296-7. PubMed ID: 15277274
[No Abstract] [Full Text] [Related]
13. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
14. [Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature].
He HS; Su GP; Chen BB
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):477-8. PubMed ID: 22213870
[No Abstract] [Full Text] [Related]
15. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Simpson E; O'Brien SG; Reilly JT
Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.
Angelopoulou MK; Asimakopoulos JV; Galani Z; Levidou G; Roumelioti M; Vassilakopoulos TP; Korkolopoulou P; Panayiotidis P
Blood Cancer J; 2016 Aug; 6(8):e461. PubMed ID: 27564459
[No Abstract] [Full Text] [Related]
18. Doctors condemn NICE's guidance on leukaemia drug.
Mayor S
BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
[No Abstract] [Full Text] [Related]
19. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
Altintas A; Cil T; Kilinc I; Kaplan MA; Ayyildiz O
J Neurooncol; 2007 Aug; 84(1):103-5. PubMed ID: 17318411
[TBL] [Abstract][Full Text] [Related]
20. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
